Literature DB >> 3149885

Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa.

C C Sanders1, M L Gates, W E Sanders.   

Abstract

Expression of chromosomal beta-lactamase was examined in 85 clinical isolates of Pseudomonas aeruginosa. beta-Lactamase assays with and without cefoxitin induction revealed four phenotypes of enzyme expression: low basal, inducible; moderate basal, inducible; moderate basal, constitutive; and high basal, constitutive. The isoelectric points of the major beta-lactamase bands were 9.4, 9.2, and 8.4. These results indicate that there is a limited heterogeneity in expression of chromosomal beta-lactamase of P. aeruginosa.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3149885      PMCID： PMC176040          DOI： 10.1128/AAC.32.12.1893

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa.

Authors:  M L Gates; C C Sanders; R V Goering; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

Review 2.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

3.  Characterization of beta-lactamases in situ on polyacrylamide gels.

Authors:  C C Sanders; W E Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

4.  Pseudomonas aeruginosa isolates with modified beta-lactamase inducibility: effects on beta-lactam sensitivity.

Authors:  D M Livermore; R J Williams; M A Lindridge; R C Slack; J D Williams
Journal:  Lancet       Date:  1982-06-26       Impact factor: 79.321

5.  Identification of beta-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy.

Authors:  M Matthew; A M Harris
Journal:  J Gen Microbiol       Date:  1976-05

6.  Induction kinetics of beta-lactamase biosynthesis in Pseudomonas aeruginosa.

Authors:  K Nordström; R B Sykes
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

7.  Factors that influence the evolution of beta-lactam resistance in beta-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa.

Authors:  S C Aronoff; D M Shlaes
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

8.  Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.

Authors:  F Tausk; M E Evans; L S Patterson; C F Federspiel; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

9.  Inducible type I beta-lactamases of gram-negative bacteria and resistance to beta-lactam antibiotics.

Authors:  N A Curtis; R L Eisenstadt; C Rudd; A J White
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

10.  Penetration of beta-lactam antibiotics into their target enzymes in Pseudomonas aeruginosa: comparison of a highly sensitive mutant with its parent strain.

Authors:  W Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191
View more
  9 in total

1.  Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  C C Sanders; M Peyret; E S Moland; C Shubert; K S Thomson; J M Boeufgras; W E Sanders
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  An SHV-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa.

Authors:  T Naas; L Philippon; L Poirel; E Ronco; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

Authors:  C C Sanders; M Peyret; E S Moland; S J Cavalieri; C Shubert; K S Thomson; J M Boeufgras; W E Sanders
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

4.  In vitro activity of E1040 against imipenem-resistant Pseudomonas aeruginosa strains.

Authors:  M Watanabe; E Inoue; K Katsu; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

5.  High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.

Authors:  B Giwercman; C Meyer; P A Lambert; C Reinert; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

6.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region.

Authors:  J I Campbell; O Ciofu; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Mechanism of imipenem resistance acquired by three Pseudomonas aeruginosa strains during imipenem therapy.

Authors:  U Vurma-Rapp; F H Kayser; K Hadorn; F Wiederkehr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

Review 8.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

9.  Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa.

Authors:  P Nordmann; E Ronco; T Naas; C Duport; Y Michel-Briand; R Labia
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.